Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Breast Cancer Drug Shrinks Tumors or Slows Growth in Up to Half of Women

07.06.2004


A new and experimental breast cancer drug called lapatinib inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial, according to results of a study being presented at the annual American Society of Clinical Oncology meeting in New Orleans.


Kimberly Blackwell, M.D., assistant professor of medicine, Duke University Medical Center
CREDIT: Duke University Medical Center



Kimberly Blackwell, M.D., an oncologist from the Duke Comprehensive Cancer Center, presented data showing that 46 percent of breast cancer patients who took the oral drug for eight weeks had stable disease or tumor shrinkage. Approximately 24 percent of patients who took the drug for four months had stable disease or tumor shrinkage.

The results are quite encouraging, said Blackwell, because lapatinib is one of the first drugs to elicit a response in women whose tumors did not respond to at least two traditional therapies, including trastuzumab (Herceptin).


Trastuzumab is the front-line drug used to treat women whose tumors overproduce a growth-regulating protein called Her-2. Trastuzumab blocks the Her-2 receptor on cancer cells and inhibits its signaling, thereby shrinking or stabilizing the tumor.

But nearly one-third of tumors with Her-2 over-expression do not respond to trastuzumab, said Blackwell. In the current trial, the majority of patients -- 59 percent -- had progressed through three, four or five traditional cancer drugs.

Lapatinib represents a new type of therapy because it targets Her-2 plus another growth factor protein called Epidermal Growth Factor (EGFR). "Blocking the action of two growth factors has a more profound effect on inhibiting cell growth than blocking a single growth factor, and we think this dual action on breast cancer cells is responsible for the positive effects we’re seeing," said Blackwell. The study was funded by GlaxoSmithKline, the maker of lapatinib.

The study showed that lapatinib was safe and had minimal side effects, because it targets only these two very specific receptor sites on breast cancer cells, said Blackwell. Five percent of women experienced a rash, 5 percent had fatigue, and 10 percent had diarrhea. In contrast, chemotherapy can cause debilitating nausea, anemia, fatigue and the potential for heart and liver damage.

The trial is continuing to recruit patients at Duke and other sites around the country.

Becky Levine | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7649

More articles from Health and Medicine:

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

nachricht Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection

13.11.2018 | Life Sciences

Fish recognize their prey by electric colors

13.11.2018 | Life Sciences

Ultrasound Connects

13.11.2018 | Awards Funding

VideoLinks
Science & Research
Overview of more VideoLinks >>>